# **Emergencies (Service Provider) Approval** 2023 (No 3)

### Notifiable instrument NI2023-689

made under the

**Emergencies Act 2004, s 62 (Decision about approval)** 

## 1 Name of instrument

This instrument is the *Emergencies (Service Provider) Approval 2023 (No 3)*\*.

### 2 Commencement

This instrument commences on the day after its notification day.

# 3 Approval

I approve OPSTAR Pty Ltd (the provider) to provide ambulance services (the services) at events in the ACT.

# 4 Conditions of Approval

Approval is subject to the conditions in Schedule 1.

# 5 Expiry

This instrument expires 12 months after the day it is notified.

Mick Gentleman MLA Minister for Police and Emergency Services

10 November 2023

#### SCHEDULE 1

#### CONDITIONS OF APPROVAL

- 1. The provider must comply with all conditions set out in the Application for Approval to Provide Ambulance Services in the ACT AF2015-140.
- 2. The provider must seek the consent of the Chief Officer, ACT Ambulance Service to provide the services at an event which was not specified in the application for approval, at least 7 days prior to the commencement of the event. The request must specify the dates and event precinct where the services are proposed to be provided, and any consent granted is subject to the services being delivered as specified in the request.
- 3. The provider must not transport any patient outside the event precinct notified to the Chief Officer, ACT Ambulance Service.
- 4. Only the personnel nominated in the provider's application for approval under section 61 of the Emergencies Act 2004 are permitted to provide the services. Staff not nominated in the application for approval may only provide the services with the Chief Officer ACT Ambulance Service's prior written approval.
- 5. The provider must provide the Chief Officer, ACT Ambulance Service copies of any updated or renewed insurance documentation if insurance is renewed during the approval period.
- 6. The provider must provide the Chief Officer, ACT Ambulance Service copies of any clinical or pharmaceutical management guidelines implemented or amended during the approval period.